IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES AMONG LEISHMANIA SPECIES

利什曼原虫物种之间差异表达基因的鉴定

• 批准号: 8360069
• 负责人: ALISON M SHAKARIAN
• 金额: $ 1.81万
• 依托单位: UNIVERSITY OF RHODE ISLAND
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360069
• 关键词: Africa; Area; Behavioral Research; Biomedical Research; Cloning; Collection; Complementary DNA; Contracts; DNA Sequence Analysis; Development; Disease; Funding; Gene Expression; Genes; Goals; Grant; India; Latin America; Leishmania; Leishmaniasis; Middle East; National Center for Research Resources; Parasites; Pharmaceutical Preparations; Pharmacotherapy; Principal Investigator; Proteins; Research; Research Infrastructure; Resources; Risk; Source; United States National Institutes of Health; Virulence; cost; human disease; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The long term goal of this project is to identify and characterize differentially expressed genes in Leishmania that may be used as potential novel targets for the development of new drug therapies for the treatment of leishmaniasis. At least 12 million people in Africa, India and Latin America are infected with Leishmania, and 350 million are at risk. Moreover, the thousands of US troops currently deployed in endemic areas (i.e. the Middle East) are at significant risk for contracting the parasite and significant disease. It is poorly understood which genes and how many proteins are involved in the survival and virulence of the pathogenic species of Leishmania. We hypothesize that differences in the expression of genes among and between pathogenic and non pathogenic species should identify some of the genes that are critical to the survival and important to the virulence of these parasites. Thus, in the current study we will identify differentially expressed genes between pathogenic and nonpathogenic species of Leishmania by cDNAAFLP and subsequently characterize these genes by sub cloning the amplified fragments and subjecting them to DNA sequence and analyses. The characterization of genes differentially expressed between pathogenic and non pathogenic species is a first step in identifying potential novel targets for the development of nontoxic drugs to be used in the treatment of leishmaniasis, a devastating and potentially fatal collection of human diseases.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 该项目的长期目标是识别和表征利什曼尼亚（Leishmania）中差异表达的基因，这些基因可能被用作开发新药疗法的潜在新靶标，以治疗利什曼病。非洲，印度和拉丁美洲至少有1200万人感染了利什曼尼亚，有3.5亿人处于危险之中。此外，目前部署在地方性地区（即中东）的成千上万的美军面临着寄生虫和重大疾病的巨大风险。鲜为人知的是，哪些基因以及有多少蛋白在利什曼原虫病原体的生存和毒力中涉及。 我们假设致病物种和非致病物种之间基因表达的差异应识别一些对生存至关重要的基因，对这些寄生虫的毒力至关重要。因此，在当前的研究中，我们将通过cDNA AFLP确定利什曼原虫的致病性和非对病毒物种之间的差异表达基因，然后通过将扩增的片段克隆并将其进行DNA序列和分析来表征这些基因。致病和非致病物种之间差异表达的基因的表征是确定潜在的新型靶标，用于用于治疗利什曼病的无毒药物的发展，这是毁灭性且可能致命的人类疾病。